Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Gains from Sales and Divestitures (2017 - 2025)

UroGen Pharma (URGN) has disclosed Gains from Sales and Divestitures for 9 consecutive years, with $557380.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Sales and Divestitures rose 44.75% year-over-year to $557380.0, compared with a TTM value of $557380.0 through Dec 2025, up 44.75%, and an annual FY2025 reading of $557380.0, up 44.75% over the prior year.
  • Gains from Sales and Divestitures was $557380.0 for Q4 2025 at UroGen Pharma, up from $385065.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $557380.0 in Q4 2025 and bottomed at $283147.0 in Q4 2021.
  • Average Gains from Sales and Divestitures over 5 years is $378702.2, with a median of $374293.0 recorded in 2022.
  • The sharpest move saw Gains from Sales and Divestitures soared 229.42% in 2021, then decreased 21.55% in 2023.
  • Year by year, Gains from Sales and Divestitures stood at $283147.0 in 2021, then soared by 32.19% to $374293.0 in 2022, then fell by 21.55% to $293626.0 in 2023, then skyrocketed by 31.14% to $385065.0 in 2024, then skyrocketed by 44.75% to $557380.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for URGN at $557380.0 in Q4 2025, $385065.0 in Q4 2024, and $293626.0 in Q4 2023.